ロード中...

Evolution of Therapies for Chronic Myelogenous Leukemia

The clinical outcome for patients with chronic myeloid leukemia (CML) has changed dramatically in the past 15 years. This has been due to the development of tyrosine kinase inhibitors (TKI), compounds which inhibit the activity of the oncogenic BCR-ABL1 protein. Imatinib was the first TKI developed...

詳細記述

保存先:
書誌詳細
主要な著者: Santos, Fabio P S, Kantarjian, Hagop, Quintás-Cardama, Alfonso, Cortes, Jorge
フォーマット: Artigo
言語:Inglês
出版事項: 2011
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3243359/
https://ncbi.nlm.nih.gov/pubmed/22157290
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/PPO.0b013e31823dec8d
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!